UBS Group’s BioNexus Gene Lab BGLC Stock Holding History

UBS Group’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$495	Buy	+231	New	+$629	﹤0.01%	9865
2025 Q4	–	Sell	-7,626	Closed	-$41.7K	–	10517
2025 Q3	$41.7K	Sell	7,626 -1,936	-20%	-$10.8K	﹤0.01%	7694
2025 Q2	$29.4K	Buy	+9,562	New	+$27.6K	﹤0.01%	8173
2025 Q1	–	Sell	-10,963	Closed	-$38.7K	–	10159
2024 Q4	$30.7K	Buy	10,963 +2,632	+32%	+$8.67K	﹤0.01%	7586
2024 Q3	$37.1K	Buy	+8,331	New	+$37.5K	﹤0.01%	7013
2024 Q2	–	Sell	-842	Closed	-$5.94K	–	9527
2024 Q1	$5.94K	Buy	+842	New	+$5.52K	﹤0.01%	7496

Other funds holding BGLC

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's BGLC Position: Q1 2026 in Review

UBS Group opened a new position in BioNexus Gene Lab (BGLC) in Q1 2026: 231 shares worth $495. The stake represents ﹤0.01% of the portfolio and ranks #9865 among its holdings. This is a return to the name: UBS Group previously reported a position in BGLC as recently as Q3 2025.

UBS Group first reported a position in BGLC in Q1 2024 and has held it in 6 quarters since. The position peaked at $41.7K in Q3 2025. 2 funds tracked by Wall St. Rank hold BGLC as of Q1 2026.

UBS Group held 231 shares of BioNexus Gene Lab worth $495 as of Q1 2026.
BioNexus Gene Lab was a new UBS Group position in Q1 2026.
BioNexus Gene Lab made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9865 holding.
UBS Group first reported a position in BioNexus Gene Lab in Q1 2024 and has held it in 6 quarters since.
UBS Group's BioNexus Gene Lab position peaked at $41.7K in Q3 2025.
2 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.